Strategically aligning your company internally and externally creates new leverage for growth in 2013.Continue reading
Author Archive: AZBio
New Force in Arizona Lobbying: Willetta Partners
Veterans Haener & Tassinari Joined by New Partner Tom FarleyContinue reading
BioCentury This Week Looks at Innovation and Incentives
Academic scientists might not like to admit it, but science and money are joined at the hip.Continue reading
President Hart Outlines UA Goals, Strategies to ABOR
UA President Ann Weaver Hart presented the University’s goals and strategies to reach them during the second day of the Arizona Board of Regents meeting on the UA campus.Continue reading
UA Cancer Center – Phoenix Project Approved for Construction
The Arizona Board of Regents has given final project approval for construction of The University of Arizona Cancer Center – Phoenix outpatient clinic at the Phoenix Biomedical Campus.Continue reading
Partners work together to accelerate development of new treatments for multiple sclerosis
The National Multiple Sclerosis Society and Critical Path Institute Create the Multiple Sclerosis Outcome Assessments ConsortiumContinue reading
TGen-US Oncology Research data guides treatment of metastatic triple-negative breast cancer patients
Unprecedented genomic sequencing of 14 metastatic TNBC patients yields potential drug targetsContinue reading
Crow, Newfeld elected AAAS Fellows
Two faculty members of Arizona State University, including ASU President Michael Crow, are among the 702 newly elected American Association for the Advancement of Science (AAAS) Fellows. A prestigious international scientific society, AAAS is the world’s largest general scientific society.Continue reading
IRS Issues Final Medical Device Regulations
The Internal Revenue Service today released the final regulations on the Medical Device Tax which will go into effect in January of 2013 unless it is repealed between now and the end of the calendar year.
Industry groups from across the country have been actively working with both the IRS and with Congress to share with them the far reaching impacts that the tax will have on both new innovations and currrent products developed and/or manufactured on shore.
In a report earlier today, Damian Garde of Fierce Biotechg shared: that the agency is adopting very few of the suggested changes to the law’s major provisions.
“The final regulations do not adopt this suggestion.” That’s a phrase you get used to when reading the IRS’s 58-page document on the 2.3% tax. Commenters had asked for exceptions for devices with medical and non-medical uses, more specific definitions of “taxable medical devices” and provisions that would account for a device’s pricing before applying the tax, among other things.
All of these were weighed, debated and ultimately rejected by the IRS, which by and large affirmed its last guidance, something we covered in detail last month. In sum, that leaves a 2.3% tax on medical devices as defined by the FDA, with exemptions for devices that are sold directly to consumers, destined for further manufacture or slated to be sold outside the U.S. (Source: IRS pays little mind to industry feedback in final device tax regs – FierceMedicalDevices )
The new IRS regulations cover 58 pages. To download a copy, please click here: Medical Device Tax Final Rules 2012-29628_PI
RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
RiboMed Biotechnologies Inc., a leading Epigenetics-Based Diagnostics company, today announced that the U.S. Patent and Trademark Office has issued three additional patents covering the use of their core technology, Abscription® (Abortive Transcription), for disease and biowarfare agent related biomarker detection. The patents expand protection to MethylMagnet® and MethylMeter®, RiboMed’s bisulfite-free DNA methylation detection products and assays, including a new prognostic test for brain cancer, G-CIMP DecisionDx. Continue reading